PacBio should return to growth over time, says Canaccord
Canaccord reiterates a Buy rating on PacBio (PACB) with a $3 price target following the company’s Q4 report. The firm says that although PacBio ...
PacBio reports Q4 EPS (20c), consensus (17c)
Reports Q4 revenue $39.22M, consensus $40.68M. “2024 was a challenging yet transformative year for PacBio (PACB), marked by the successful ...
The Business Journals16d
Menlo Park-based biotech company welcomes Florida exec to board
The company is known for pioneering DNA sequencing. Chris Smith, CEO of oncology diagnostic company NeoGenomics Inc., is getting a seat on the board of Pacific Biosciences of California Inc ...